Statement by Michael A. Carrier to House Energy & Commerce Committee (Subcommittee on Consumer Protection and Commerce)
House Subcommittee of House Energy & Commerce Committee hearing September 19, 2019
3 Pages Posted: 22 Oct 2019
Date Written: September 19, 2019
Drug companies have engaged in "product hopping," reformulating a drug so a generic can't be substituted while encouraging doctors to prescribe the new version. My statement (1) defines the activity, (2) reveals harms suffered by consumers, (3) offers concerning examples, (4) shows how product hopping harms innovation, and (5) provides solutions.
Keywords: antitrust, pharmaceuticals, drugs, product hopping
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation